Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Ujejskiego 75 Street, 85-168 Bydgoszcz, Poland.
Department of Nutrition and Dietetics, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Dębowa 3 Street, 85-626 Bydgoszcz, Poland.
Int J Mol Sci. 2021 Aug 8;22(16):8531. doi: 10.3390/ijms22168531.
Cardiovascular diseases are the most common cause of death in the world. For almost 60 years, vitamin K antagonists (VKAs) were the mainstay of anticoagulation therapy, but in recent years direct oral anticoagulants (DOACs) have become the anticoagulant treatment of choice. DOACs were initially considered drugs with no significant food interactions; however, clinical observations from daily practice have proved otherwise as interactions with food ingredients have been reported. Food, dietary supplements or herbs may contain substances that, when administered concomitantly with DOACs, can potentially affect the plasma concentration of the drugs. The aim of this paper was to evaluate the clinical significance of drug-food interactions of DOACs, such as dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban. Patients treated with anticoagulants should avoid products containing and take special care with other food ingredients. As the interest in dietary supplements is on the rise, healthcare providers can contribute to the development of well-designed clinical trials on interactions between DOACs and food, and distribute sufficient knowledge about the proper use of these supplements among patients.
心血管疾病是世界上最常见的死亡原因。近 60 年来，维生素 K 拮抗剂 (VKA) 一直是抗凝治疗的主要药物，但近年来，直接口服抗凝剂 (DOAC) 已成为抗凝治疗的首选。DOAC 最初被认为是与食物无明显相互作用的药物；然而，来自日常实践的临床观察证明并非如此，因为已经报道了与食物成分的相互作用。食物、膳食补充剂或草药可能含有物质，当与 DOAC 同时给药时，可能会影响药物的血浆浓度。本文旨在评估 DOAC（如达比加群、利伐沙班、阿哌沙班、依度沙班和贝曲沙班）的药物-食物相互作用的临床意义。接受抗凝治疗的患者应避免含有 的产品，并特别注意其他食物成分。由于对膳食补充剂的兴趣日益增加，医疗保健提供者可以为设计良好的 DOAC 与食物相互作用的临床试验做出贡献，并在患者中传播关于正确使用这些补充剂的足够知识。
